Similar articles

• [Clinical problems in the application of sedatives in patients with chronic liver disease (author's transl)].

  Becker K. Becker K. Z Gastroenterol. 1977 Jun;15(6):356-61. Z Gastroenterol. 1977. PMID: 888484 German.
• The disposition and effects of sedatives and analgesics in liver disease.

  Hoyampa AM Jr, Branch RA, Schenker S. Hoyampa AM Jr, et al. Annu Rev Med. 1978;29:205-18. doi: 10.1146/annurev.me.29.020178.001225. Annu Rev Med. 1978. PMID: 348033 Review. No abstract available.
• The effect of parenchymal liver disease on the disposition and elimination of sedatives and analgesics.

  Schenker S, Hoyumpa AM Jr, Wilkinson GR. Schenker S, et al. Med Clin North Am. 1975 Jul;59(4):887-96. doi: 10.1016/s0025-7125(16)31987-3. Med Clin North Am. 1975. PMID: 238085 Review. No abstract available.
• [Drug metabolism in patients with liver disease (author's transl)].

  Richter E, Epping J, Fuchshofen-Röckel M, Heusler H, Zilly W. Richter E, et al. Leber Magen Darm. 1980 Oct;10(5):234-40. Leber Magen Darm. 1980. PMID: 7464410 German.
• [Metabolism of phenylbutazone in the liver (author's transl)].

  González Macías J, De Castro del Pozo S. González Macías J, et al. Med Klin. 1976 Sep 3;71(36):1434-8. Med Klin. 1976. PMID: 958107 German.